Is Duratec (ASX: DUR) a Buy After the PNG Contract Win, or Has the Rally Run Its Course?

Ujjwal Maheshwari Ujjwal Maheshwari, March 30, 2026

Duratec Shares Rise on Newmont PNG Contract

Duratec (ASX: DUR) landed a significant A$45 million contract from Lihir Gold, a subsidiary of global mining giant Newmont. It is a meaningful win that confirms the company’s growing reach beyond its home market. The market responded positively, with shares rising 3.32% on the day, though the stock remains near its 52-week high. After a strong run over the past 12 months, investors face a genuine question: Does this contract give you a reason to buy today, or is the good news already baked into the price?

What are the Best ASX Industrial Stocks to invest in right now?

Check our buy/sell tips

Duratec Deepens Its Energy and Resources Push With the Newmont PNG Win

The 12-month contract involves Duratec’s wholly owned subsidiary, Duratec (PNG), providing specialised plug and abandonment services at the Lihir Operations in Papua New Guinea. In simple terms, the work involves safely decommissioning existing wells as part of Phase 1 of the Lihir Nearshore Soil Barrier Project. Work starts immediately.

The real significance goes beyond the revenue figure. Newmont is one of the world’s largest gold miners, and securing work in Papua New Guinea shows Duratec can compete for Tier-1 contracts outside Australia. We believe this contract genuinely strengthens the long-term investment case. The ability to mobilise quickly in a new geography for a major global miner reflects real operational credibility, and if the Newmont relationship deepens, it could unlock further international work down the track.

A Business Built Across Multiple Sectors, With Defence Leading the Way

What makes Duratec an interesting company is how it operates across four distinct segments: Defence, Mining and Industrial, Building and Facade, and Energy. This spread gives the business a natural buffer when one sector slows down.

Defence remains the largest revenue driver, and the long-term outlook here is strong. Duratec has a well-established presence at HMAS Stirling and is well-positioned to benefit from Australia’s growing defence spending, including the AUKUS nuclear submarine program. The PNG contract now adds meaningful momentum to the Energy segment, which is exactly the kind of diversification management has been targeting. The broader story here is a company that is no longer just a defence contractor; it is becoming a genuine multi-sector infrastructure services business.

The Investor’s Takeaway

Duratec is a well-run business with solid foundations. Half-year results released in February 2026 showed trailing 12-month revenue of around A$559 million with net profit margins improving slightly to 4.2% and return on equity sitting at a healthy 27.5%.

The challenge for new investors is valuation. The stock has climbed around 45% over the past year and currently trades near A$2.49, at or above the top of most analyst price targets. The stock also trades on a price-to-earnings multiple of between 24 and 28  times, noticeably higher than the broader construction sector average.

In our view, Duratec is a quality operator executing well. But much of the optimism already appears reflected in the share price. A pullback toward the A$2.10 to A$2.20 range could offer a more attractive entry point without giving up the long-term story. Patient investors may be rewarded for waiting.

Blog Categories

Get the Latest Insider Trades on ASX!

Recent Posts

Freightways (ASX:FRW): You probably haven’t heard of this $2bn Kiwi company in the ASX 200, but here’s why it could be worth a look

Every time a parcel travels across the Tasman or a courier van pulls up outside an Auckland office, there is…

Why Do Stocks With Better Fundamentals Trail Their Peers? And When Should You Accept Waiting for a Re-Rating Is a Lost Cause?

Stocks with better fundamentals trail their peers – that’s just the reality of the market. But why? What are the…

Best ASX Healthcare Stocks to Buy as the Sector Trades at Two-Decade Valuation Lows

ASX Healthcare Stocks to Buy at Valuation Lows ASX healthcare stocks have had a brutal run. Five years of underperformance,…